LONDON (Alliance News) - Vectura Group PLC said Tuesday its partner Ablynx Nv has opted to exercise its commercial licence option for Vectura's smart nebuliser technology, and progress Ablynx's compound ALX-0171 into a phase IIb dose-ranging efficacy study.
This follows positive top line results announced in May from a phase I/IIa study of ALX-0171 for the treatment of respiratory syncytial virus in infants.
"We are pleased with the confirmation of the progress of this programme and our continued collaboration with Ablynx. This is an important programme in the development of new treatment options for RSV in vulnerable patient populations. This announcement also demonstrates the utility of the Vectura smart nebuliser technology and the value of a strong partnering relationship combining the device capabilities of Vectura and the powerful Nanobody technology and development expertise of Ablynx," said Chief Executive Officer James Ward-Lilley in a statement.
Shares in Vectura were up 2.2% at 151.00 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
